That's a big improvement of the last such report, in 2001, when the company said it had only two drugs at the same stage of development, the Wall Street Journal reported Friday.
The drugmaker attributes its improved output to improved research productivity, a slew of acquisitions and aggressive licensing. The experimental drugs treat illnesses that include the AIDS virus and various cancers.
Other prospects include dapoxetine, a pill for premature ejaculation; paliperidone, an antipsychotic related to Risperdal; and Yondelis, for soft-tissue sarcoma.
Couple calls 9-1-1 over missing hash browns; assault McDonanld's employees
Exploding whale video goes viral on Internet